Helicobacter Pylori Infection and Gastric Diseases in Lao PDR: First Community-Wide Population-Based Study
NCT ID: NCT07340593
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1251 participants
OBSERVATIONAL
2023-12-18
2025-06-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Community-based Helicobacter Pylori Eradication
NCT00155389
Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study
NCT07211880
Registry for the Management of Helicobacter Pylori Infection in Shandong Province
NCT07335406
Prospective Study : Helicobacter Pylori Eradication Therapy in Accordance With Past Antibiotics Use
NCT01938534
Clinical Experiment of Helicobacter Pylori Transmission
NCT00550368
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible participants were residents aged ≥18 years living in Luang Prabang Province (North) and Champasak Province (South). The study received approval from the Ethics Committee of the Ministry of Health of Laos. All participants received an explanation of the risks and benefits of screening and provided written informed consent.
The study procedures were conducted as follows:
1. Stool H. pylori antigen rapid test was performed for all enrolled participants.
2. Participants aged ≥40 years who tested positive were considered a high-risk group and underwent upper gastrointestinal endoscopy for early detection of precancerous gastric lesions and gastric cancer.
3. All H. pylori-positive participants received 14-day triple therapy consisting of lansoprazole, amoxicillin, and clarithromycin.
4. Eradication was assessed using a follow-up stool antigen test at 8 months after treatment in Luang Prabang Province and 6 months after treatment in Champasak Province.
Screening in Luang Prabang Province was conducted between December 2023 and October 2024, and screening in Champasak Province between October 2024 and June 2024.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Residents of Luang Prabang Province
Residents aged ≥18 years in Luang Prabang Province who underwent stool antigen testing for H. pylori.
Participants ≥40 years who tested positive additionally underwent upper endoscopy.
All positive individuals received triple therapy and were followed for eradication.
No interventions assigned to this group
Residents of Champasak Province
Residents aged ≥18 years in Champasak Province who underwent stool antigen testing for H. pylori.
Participants ≥40 years who tested positive additionally underwent upper endoscopy.
All positive individuals received triple therapy and were followed for eradication.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Resident of Luangprabang or Champasak Province
* Able to provide written informed consent
Exclusion Criteria
* Allergy to medications used in triple therapy
* Pregnant or breastfeeding women (if applicable)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oita University
OTHER
Setthathirath Hospital
OTHER
Mahosot Hospital, Laos
UNKNOWN
Lao National Cancer Center
OTHER
Zero Helicobacter IGAN Network
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center
Vientiane, Capital, Laos
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1015/REC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.